1. Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer
   Silvia Nuzzo et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
2. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
   Luís Eduardo Zucca et al, 2018, Urologic Oncology: Seminars and Original Investigations CrossRef
3. Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies
   Ruth Dannenfelser et al, 2020, Cell Systems CrossRef
4. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
   Valeriy Poroyko et al, 2018, Oncotarget CrossRef
5. AXL is a marker for epithelial‑mesenchymal transition in esophageal squamous cell carcinoma
   Guoan Zhang et al, 2017, Oncology Letters CrossRef
6. Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival
   Lakhveer Singh et al, 2023, Frontiers in Oncology CrossRef
7. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy
   Linsheng Zhuo et al, 2024, European Journal of Medicinal Chemistry CrossRef
8. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
   Jonathan Rios-Doria et al, 2020, Frontiers in Oncology CrossRef
9. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
   Mariam Fatima et al, 2021, BMC Cancer CrossRef
10. AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers
    Xiaobai Sun et al, 2023, Molecular and Clinical Oncology CrossRef
11. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells
    Youn Lee et al, 2019, Molecular Medicine Reports CrossRef
12. The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer
    Baijiao An et al, 2019, European Journal of Medicinal Chemistry CrossRef
13. Establishment of a novel efferocytosis potential index predicts prognosis and immunotherapy response in cancers
    Peng Chen et al, 2024, Heliyon CrossRef
14. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
    Dandan Xu et al, 2021, European Journal of Medicinal Chemistry CrossRef
15. In vitro anti-cancer activity of a polyherbal preparation, VEDICINALS®9, against A549 human lung adenocarcinoma cells
    Keshav Raj Paudel et al, 2023, Pathology - Research and Practice CrossRef
16. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer
    Floriana Morgillo et al, 2017, Journal of Medicinal Chemistry CrossRef
17. Evaluation of the Cytotoxic Activity and Anti-Migratory Effect of Berberine–Phytantriol Liquid Crystalline Nanoparticle Formulation on Non-Small-Cell Lung Cancer In Vitro
    Abdullah Alnuqaydan et al, 2022, Pharmaceutics CrossRef
18. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
    Yi‐Nan Liu et al, 2019, International Journal of Cancer CrossRef